Brief: InnoCare, Zenas sign global licensing pact worth over $2 bln
08/10/2025 10:55
Oct 8 (Reuters) - InnoCare Pharma Ltd 688428.SS: ZENAS BIOPHARMA AND INNOCARE PHARMA ANNOUNCE LICENSE AGREEMENT GRANTING ZENAS RIGHTS FOR THREE AUTOIMMUNE PRODUCT CANDIDATES, INCLUDING ORELABRUTINIB, A BTK INHIBITOR IN PHASE 3 DEVELOPMENT FOR MULTIPLE SCLEROSIS ZENAS BIOPHARMA: ANNOUNCES $120 MILLION PRIVATE PLACEMENT FINANCING ZENAS BIOPHARMA INC - NOVEL ORAL IL-17AA/AF INHIBITOR, AND AN ORAL, BRAIN-PENETRANT, TYK2 INHIBITOR, EXPECTED TO BEGIN PHASE 1 CLINICAL TRIALS IN 2026 ZENAS BIOPHARMA: TO PAY INNOCARE UPFRONT & NEAR-TERM MILESTONE PAYMENTS UP TO $100 MILLION IN CASH Source text: ID:nGNX2vPXP1 Further company coverage: 688428.SS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints